Brokerages Set Corium International, Inc. (CORI) Price Target at $10.30

Corium International, Inc. (NASDAQ:CORI) has been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $10.30.

Several research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Corium International in a research report on Friday, April 14th. Zacks Investment Research lowered Corium International from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. FBR & Co reaffirmed an “outperform” rating and issued a $13.00 target price (up from $12.00) on shares of Corium International in a research report on Tuesday, April 18th. ValuEngine raised Corium International from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC set a $8.00 price target on Corium International and gave the company a “buy” rating in a report on Thursday, April 20th.

In other Corium International news, major shareholder Perceptive Advisors Llc bought 1,902,400 shares of the stock in a transaction dated Thursday, May 25th. The stock was bought at an average cost of $6.25 per share, for a total transaction of $11,890,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 45.70% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in CORI. Bank of New York Mellon Corp increased its stake in shares of Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 13,683 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Corium International by 0.6% in the first quarter. Geode Capital Management LLC now owns 69,552 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 444 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Corium International by 44.1% in the first quarter. Vanguard Group Inc. now owns 500,965 shares of the biopharmaceutical company’s stock valued at $2,094,000 after buying an additional 153,358 shares during the last quarter. Royce & Associates LP boosted its position in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares during the last quarter. Finally, RTW Investments LLC boosted its position in shares of Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares during the last quarter. Institutional investors own 77.47% of the company’s stock.

Corium International (NASDAQ:CORI) traded down 3.61% during trading on Tuesday, hitting $7.20. The stock had a trading volume of 162,381 shares. The company’s market cap is $210.47 million. Corium International has a 12 month low of $2.67 and a 12 month high of $8.33. The company’s 50 day moving average is $6.35 and its 200-day moving average is $4.64.

Corium International (NASDAQ:CORI) last issued its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.05. The firm had revenue of $7.35 million during the quarter, compared to analysts’ expectations of $6.05 million. Corium International had a negative return on equity of 1,550.00% and a negative net margin of 116.59%. On average, equities research analysts predict that Corium International will post ($1.69) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is owned by of BBNS. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://baseballnewssource.com/markets/corium-international-inc-cori-receives-average-rating-of-buy-from-brokerages-updated/994877.html.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.